China's WuXi PharmaTech Leads $15 Million Investment in Claritas Genomics
publication date: Feb 2, 2015
WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech, led a $15 million Series B financing in Claritas Genomics. Claritas is a Boston-based lab that develops and provides next-gen sequence-based tests for pediatric genomic disorders. The company was spun out of Boston Children’s Hospital two years ago with assistance from Life Technologies. WuXi NextCODE was formed earlier this year when WuXi PharmaTech paid $65 million to acquire NextCODE Health, a genomics sequencing company. More details....
Stock Symbols: (NYSE: WX) (NSDQ: LIFE)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.